Image
Practice Point
Management of the axilla – After neoadjuvant systemic therapy
Management of an axilla that becomes sentinel node negative after neoadjuvant systemic therapy is an emerging aspect of care and no definitive guidance can currently be given.
There is no firm evidence base to advise on the treatment of patients presenting with biopsy-proven axillary node metastases who then are found, after NACT, to have a complete pathological response in their SNB (ypN0). Until there is an improved evidence base for this group of patients (ypN0 on post-NACT SNB) they should be offered axillary radiotherapy
How this guidance was developed
No evidence-based source recommendation was identified for this topic, which was considered an important aspect of care. This practice point was developed using an expert consensus process.
It is supported by recent guidance from the Association of Breast Surgery, Faculty of Clinical Oncology of the Royal College of Radiologists, UK Breast Cancer Group, National Coordinating Committee for Breast Pathology and British Society of Breast Radiology (2019).
Management of the axilla – After neoadjuvant systemic therapy
Practice Point
Management of an axilla that becomes sentinel node negative after neoadjuvant systemic therapy is an emerging aspect of care and no definitive guidance can currently be given.
Principles in action
Safe and quality care
No evidence-based source recommendation was identified for this topic, which was considered an important aspect of care. This practice point was developed using an expert consensus process.
It is supported by recent guidance from the Association of Breast Surgery, Faculty of Clinical Oncology of the Royal College of Radiologists, UK Breast Cancer Group, National Coordinating Committee for Breast Pathology and British Society of Breast Radiology (2019).